TricValve: 12-Month Evolution

Tricuspid regurgitation has become increasingly common, and current pharmacological treatment options are limited. In turn, surgery, which is a complex alternative, carries considerable rates of complications and mortality.

TricValve: evolución a 12 meses

In response to this issue, various percutaneous systems are being developed, such as edge-to-edge treatment, percutaneous annuloplasty, and caval valve implantation (CAVI), among others.

In the analysis conducted in the TRICUS and TRICUS EURO studies, which included 44 patients, the primary endpoint (PE) was defined as changes in quality of life (QOL) as assessed by KCCQ-12, functional class, and the 6-minute walk test (6MWT) at 12 months.

The average participant age was 76 years, and most subjects were women. All of them were classified in functional categories III-IV. Among the population, 33 patients had hypertension, 7 had diabetes, 42 experienced atrial fibrillation, 6 had coronary artery disease, 2 had chronic obstructive pulmonary disease (COPD), 9 had undergone permanent pacemaker implantation, and 29 showed impaired renal function. Regarding valves, 7 patients had undergone aortic valve replacement, 12 had mitral valve replacement, and 7 had tricuspid valve replacement, while 2 had undergone transcatheter aortic valve replacement (TAVR), 3 had undergone percutaneous mitral treatment, and 1 had prior percutaneous tricuspid treatment.

Read also: Evolution of Bicuspid Valves at 12 Months.

The left ventricular ejection fraction was 59%, the TRISCORE was 5.1%, and the EUROSCORE II was 5.6%. All patients had high BNP levels, with a KCCQ-12 of 40 and a 6MWT of 229 meters.

The PE was achieved in 42 out of 44 patients (95%). There was a significant improvement of more than 15 points in QOL, and all patients were in functional categories I-II (p<0.001). There was also a non-significant increase in the 6MWT (229 vs. 270 meters, p=0.285).

After one year, 3 patients died (all-cause mortality): one of them had required tricuspid surgery. There were 9 cases of major bleeding, 4 cases of strokes, and 13 rehospitalizations for heart failure.

Conclusion

In conclusion, bicaval TricValve implantation showed an association with significant clinical improvement at one year in terms of quality of life, with a relatively low mortality rate.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation 1-Year Follow-Up Outcomes.

Reference: Sara Blasco-Turrión, et al. J Am Coll Cardiol Intv 2024;17:60–72.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...